SINTX Technologies Inc

SINTX Technologies Inc (SINT) Stock Analysis

$1.500

-0.029 (-1.96%)At close

Loading chart…
High
1.531
Open
1.510
VWAP
1.50
Vol
18.63K
Mkt Cap
3.17M
Low
1.480
Amount
28.02K
EV/EBITDA, TTM
-0.29

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI analysis of SINTX Technologies Inc (SINT)

hold

SINTX Technologies Inc is currently not a good buy due to its low price of $1.50, which is significantly below its analyst price targets of $6 and $10. However, the stock has a low RSI of 35.04, indicating it may be oversold. The main risk is its substantial year-to-date decline of 60.32%, suggesting ongoing challenges.

Valuation Metrics

The current forward P/E ratio for SINTX Technologies Inc (SINT) is 0.00, compared to its 5-year average forward P/E of -18.66.

Forward P/E

Fair
5Y Average P/E
-18.66
Current P/E
0.00
Overvalued
58.38
Undervalued
-95.70

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.36
Current EV/EBITDA
-0.29
Overvalued
0.29
Undervalued
-1.02

Forward P/S

Fair
5Y Average P/S
4.88
Current P/S
1.92
Overvalued
10.00
Undervalued
-0.25

Alphio AI Price Scenarios for SINT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SINT

$2.63

Scenario price

B

Base

Base · 50%SINT

$1.91

Scenario price

B

Bear

Bear · 25%SINT

$1.46

Scenario price

Events Timeline

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

2026-03-19 (ET)

07:50:00

SINTX Completes First-in-Human Surgery, Enters Global Orthopedic Market

2026-02-18 (ET)

08:40:00

Sintx Technologies Appoints Ryan Elmore as President

News

SINT FAQ — answered by Alphio AI

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is currently not a good buy due to its low price of $1.50, which is significantly below its analyst price targets of $6 and $10. However, the stock has a low RSI of 35.04, indicating it may be oversold. The main risk is its substantial year-to-date decline of 60.32%, suggesting ongoing challenges.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started